Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
FEASEBILITY AND LIMITATIONS OF EARLY AND ACCELERATED THERAPY WITH THE FOUR PILLARS FOLLOWING ACUTE DECOMPENSATED HEART FAILURE
Anno:
2025
Introduction Growing evidences suggest that an early and accelerated use of the four pillars for the treatment of acute decompensated heart failure (ADHF) may be recommended to reduce cardiovascular morbidity and mortality accross the entire spectrum of ejection fraction (EF). The aim of our study is to establish safety…
Leggi di più
CARDIOGENIC SHOCK OUTCOME: EXPERIENCE OF A SINGLE CENTER INSERTED IN A REGIONAL NETWORK FOR CARDIOGENIC SHOCK
Anno:
2025
Background:Cardiogenic shock (CS) management is challenging due to the heterogeneity of clinical presentations, complex hemodynamic perturbations and several complications.Therefore a multidisciplinary shock team and dedicated intensive cardiac care unit (ICCU) are necessary to treat these patients (pts). Purpose:To assess clinical features and outcome of CS pts treated in a…
Leggi di più
FIRST-IN-MAN USE OF VERICIGUAT IN A HEART TRANSPLANT RECIPIENT WITH LATE GRAFT FAILURE
Anno:
2025
A 41-year-old patient with late graft failure from a cardiac transplant performed 12 years earlier was referred to our unit for heart retransplantation in January 2023. Severe cardiac allograft vasculopathy (ISHLT CAV 3) not amenable to revascularization was diagnosed. Given the patient's history of multiple episodes of worsening heart failure…
Leggi di più
VERICIGUAT EFFECT ON RIGHT VENTRICULAR TO PULMONARY ARTERY COUPLING: A CASE REPORT
Anno:
2025
Introduction: In patients with pulmonary hypertension due to left heart disease (PH-LHD), optimizing treatment of the underlying condition is recommended. Vericiguat may be considered in patients who have had worsening heart failure (HF) even with guideline-directed medical therapy (GDMT), but despite its beneficial role on endothelial function, its effect…
Leggi di più
EFFICACY OF VERICIGUAT IN A PATIENT WITH HFREF AND CLINICAL STABILITY, A CASE REPORT
Anno:
2025
Heart failure (HF) is a syndrome whit complex etiology associated with high mortality and hospitalization risk, despite therapeutic progress. Recent ESC (European Society of Cardiology) guidelines recommend vericiguat use in patients with reduced ejection fraction (HFrEF) with optimal medical therapy and recent episode of HF exacerbation (class IIb). Some…
Leggi di più
AGE- AND SEX-RELATED DIFFERENCES IN HEART FAILURE CHARACTERISTICS AND TREATMENT PATTERNS ACROSS THE EJECTION FRACTION SPECTRUM
Anno:
2025
Introduction: Older adults and females are under-represented in randomized clinical trials, and evidence on age – and sex-related differences in heart failure (HF) characteristics and treatment patterns is limited. Purpose: To evaluate differences in the clinical characteristics and treatments of an all-comers cohort of HF patients stratified by age…
Leggi di più
Identifying Cardiogenic Shock Sub-Phenotypes with Machine Learning: A Multicenter Study Combining Clinical and Echocardiographic Data
Anno:
2025
Background: sub-phenotyping patients with cardiogenic shock (CS) through a non-traditional clustering method may represent a significant step forward in precision medicine, enhancing clinical outcomes in this heterogeneous and high-mortality condition. We aimed to apply an unsupervised machine learning approach integrating clinical and imaging data (including advanced echocardiography) to identify…
Leggi di più
CHANGES IN INVASIVE HAEMODYNAMICS AND LEFT ATRIAL FUNCTION IN PATIENTS WITH HEART FAILURE ACCORDING TO HAEMODYNAMIC CONDITIONS
Anno:
2025
Background. Left atrial (LA) function is tightly interrelated with the haemodynamic conditions in patients with heart failure (HF). Optimisation of left ventricular (LV) haemodynamics may improve LA-LV coupling, leading to enhanced cardiac function and reduced LV filling pressures. Methods. Consecutive HF with reduced ejection fraction patients were prospectively enrolled….
Leggi di più
IN-HOSPITAL MORTALITY FROM CARDIOGENIC SHOCK IN CARDIAC INTENSIVE CARE UNIT: INSIGHTS FROM A SINGLE-CENTRE, CONTEMPORARY, REAL-WORLD STUDY
Anno:
2025
Background: Cardiogenic shock (CS) is a life-threatening syndrome characterized by a low cardiac output, followed by tissue hypoperfusion and increased lactate levels, which frequently leads to multi-organ failure and death. Despite the improvements in clinical management and therapeutic approach, in-hospital mortality remains high. The aim of the present study…
Leggi di più
PREDICT-CCM: AN ITALIAN MULTICENTER STUDY TO ASSESS THE PREDICTIVE VALUE OF DOBUTAMINE ECHO-STRESS IN THE CLINICAL RESPONSE TO CARDIAC CONTRACTILITY MODULATION THERAPY (CCM)
Anno:
2025
Background: Heart failure (HF) has a very poor prognosis in terms of mortality, quality of life, and functional capacity. When optimal medical therapy (OMT) alone is not sufficient or not well tolerated by the subject, in selected cases with cardiac conduction system disorders, it is possible to combine it…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram